Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma - Long survival with various therapeutic strategies including a lung resection: Report of a case

Surgery Today

Volumn 38, Issue 3, 2008, Pages 275-278

  Hamanaka, Wakako ^a,b   Yoneda, Satoshi ^a   Shirakusa, Takayuki ^b   Shirahama, Hiroshi ^a   Tashiro, Yukie ^a   Iwasaki, Akinori ^b   Shiraishi, Takeshi ^b   Tsuru, Hirohumi ^a  

^a Imakiire General Hospital   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Adrenocortical carcinoma; AFP producing tumor; Hemothorax; Long survival; Metastatic lung tumor

Indexed keywords

ALPHA FETOPROTEIN; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; FEMALE; HEMATOTHORAX; HUMAN; KIDNEY METASTASIS; LUNG METASTASIS; LUNG RESECTION; QUALITY OF LIFE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ALPHA-FETOPROTEINS; BRAIN NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; PNEUMONECTOMY;

EID: 40149107417     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-007-3610-9     Document Type: Article

References (21)

1. Dang C, Mohamed H, Mandal A, Salem F. Adrenal cortical carcinoma: a case of late pulmonary metastasis. J Natl Med Assoc 2001;93:37-39.
2. Norton JA, Le HN. Adrenal tumors. In: DeVita VT Jr, Hekkman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. 1770-1787.
3. Brennan MF. Adrenocortical carcinoma. CA Cancer J Clin 1987;37:348-365.
4. Wooten MD, King DK. Adrenal cortical carcinoma: epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-3155.
5. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer 2002;94:2333-2343.
6. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1993;11:161-165.
7. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, et al. Eastern Cooperative Oncology Group Study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991;110:1006-1013.
8. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-1287.
9. Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, et al. Adrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896-903.
10. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25:891-897.
11. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;332:1195-1201.
12. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112:963-971.
13. Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma: aggressive resection vs chemotherapy. Arch Surg 1991;126:457-461.
14. Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery 1986;100:1170-1176; discussion 1176-7.
15. Orlando R, Pelizzo MR, Lirussi F. Adrenocortical carcinoma: a 15-year survival after complete resection and repeated resection. A retrospective study in a patient with an expected poor prognosis. Anticancer Res 2003;23:2929-2932.
16. Favia G, Lumachi F, D'Amico D. Adrenocortical carcinoma: is prognosis different in nonfunctioning tumors? Results of surgical treatment in 31 patients. World J Surg 2001;25:735-738.
17. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery 1996;119:161-170.
18. Lee JE, Berger DH, El-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090-1098.
19. Fujii Y, Kageyama Y, Kawakami S, Masuda H, Arisawa C, Akamatsu H, et al. Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma. Int J Urol 2003;10:445-448.
20. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-950.
21. Yoshioka M, Ihara H, Shima H, Mori Y, Ikoma F, Ueno Y, et al. Adrenal hepatoid carcinoma producing α-fetoprotein: a case report (in Japanese with English abstract). Hinyoukiyou (Acta Urol Jpn) 1994;40:411-414.